Multiple Sclerosis Market Outlook, 2032 | Insights Into the Evolving Market Dynamics, Growth Opportunities, Epidemiology Trends, Emerging Therapies, Treatment Algorithm, and Key Companies

January 10 19:32 2023
Multiple Sclerosis Market Outlook, 2032 | Insights Into the Evolving Market Dynamics, Growth Opportunities, Epidemiology Trends, Emerging Therapies, Treatment Algorithm, and Key Companies
Delveinsight Business Research LLP
The Multiple Sclerosis (MS) market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies such as NeuroVax (Immune Response BioPharma), CNM-Au8 (Clene Nanomedicine), and others. Moreover, the rising research & development activities and growing prevalence of Multiple Sclerosis are also anticipated to fuel the market growth during the forecast period of 2021–2032.

The Multiple Sclerosis treatment market looks promising as the market is emerging and continuously evolving with various newer treatments that the FDA has recently designated to treat the disease. However, large multicenter trials are still necessary to examine the overarching patterns of Multiple Sclerosis and treatment response as a whole. Overall, the increasing prevalence of the disease, along with upcoming novel therapies and increasing awareness, will fuel the market in the coming years.

DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Sclerosis market size, share, and trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

The Multiple Sclerosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Multiple Sclerosis Market

Multiple Sclerosis: An Overview

Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, the body’s immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which protects the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions. There are four major categories of Multiple Sclerosis. These are Relapsing-Remitting MS, Secondary-Progressive MS, Primary-Progressive MS, and Progressive-Relapsing MS.

People with Multiple Sclerosis generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems, bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.

Multiple Sclerosis Market Key Facts

  • The Multiple Sclerosis market size in the seven major markets was found to be USD 22,381 million in 2020.

  • The total prevalent cases of Multiple Sclerosis were 1,265,000+ in 2020 in the 7MM.

  • As per DelveInsight’s estimates, in 2019, the prevalent cases of Multiple Sclerosis in the United States were found to be 708,000+ cases which will increase by 2032.

  • The prevalent population of Multiple Sclerosis in Japan in 2019 was found to be 4,800+.

  • According to DelveInsight’s estimates, the prevalence of Multiple Sclerosis is higher in females as compared to males.

  • With the continuous efforts in research and development, various companies are developing new therapies for the treatment of Multiple Sclerosis, some of which include NeuroVax (Immune Response BioPharma, Inc.), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), Ublituximab (TG Therapeutics, Inc.), ALKS 8700 (Alkermes/Biogen), Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical), Masitinib (AB Science), Fenebrutinib (Genentech), and others.

Multiple Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Multiple Sclerosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Multiple Sclerosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Multiple Sclerosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Multiple Sclerosis Epidemiology, Segmented by –

  • Total Prevalent Cases of Multiple Sclerosis in the 7MM (2019–2032)

  • Phenotype-specific prevalent cases of Multiple Sclerosis in the 7MM (2019–2032)

  • Prevalence of Multiple Sclerosis based on Age in the 7MM (2019–2032)

  • Prevalence of Multiple Sclerosis based on Gender in the 7MM (2019–2032)

  • EDSS in the 7MM (2019–2032)

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched during the study period. The analysis covers the Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Multiple Sclerosis Market Will Evolve by 2032 @

Some of the Leading Companies in the Multiple Sclerosis Therapeutics Market Include:

  • Immune Response BioPharma, Inc.

  • Clene Nanomedicine

  • Sanofi

  • Merck Healthcare KGaA

  • TG Therapeutics, Inc.

  • Apimeds Inc.

  • Bayer HealthCare

  • Novartis

  • Biogen

  • Alkermes

  • Genentech

And Many Others

Multiple Sclerosis Emerging Drugs Covered in the Report Include:

  • NeuroVax (Immune Response BioPharma, Inc.)

  • CNM-Au8 (Clene Nanomedicine)

  • Tolebrutinib (SAR442168) (Sanofi)

  • Evobrutinib/M2951 (Merck Healthcare KGaA)

  • Ublituximab (TG Therapeutics, Inc.)

  • ALKS 8700 (Alkermes/Biogen)

  • Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical)

  • Masitinib (AB Science)

  • Fenebrutinib (Genentech)

And Many Others

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Products

12. Multiple Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (In US, EU5, and Japan)

16. Multiple Sclerosis Access and Reimbursement Overview

17. KOL Views on the Multiple Sclerosis Market

18. Multiple Sclerosis Market Drivers

19. Multiple Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download Sample PDF to Explore the Key Offerings of the Report:

Other Trending Healthcare Reports By DelveInsight

Multiple Sclerosis Pipeline Insight

Multiple sclerosis – Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ drugs in the Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author